ABSTRACT
A survey carried out in France at the beginning of 1984 concerning development of children born of mothers treated with bromocriptine (BC) during part or all of the pregnancy showed the absence of any adverse effects of BC in 64 children born from 53 mothers. In 60 cases, BC was prescribed (2.5-7.5 mg/day) for hyperprolactinemia; 23 mothers were treated with BC for 4 weeks or less, and 23 others for 30 weeks or more. After a follow-up of between 6 months and 9 years, all children are normal. Psychological development in the 23 children born to mothers treated with BC during more than 30 weeks of pregnancy actually appears more precocious, with excellent scholastic performance in the oldest.
Subject(s)
Adenoma/drug therapy , Bromocriptine/therapeutic use , Child Development/drug effects , Maternal-Fetal Exchange , Pituitary Neoplasms/drug therapy , Pregnancy Complications, Neoplastic/drug therapy , Pregnancy/drug effects , Birth Weight , Female , Follow-Up Studies , Humans , Infant, Newborn , Male , Pregnancy Trimester, First , Pregnancy Trimester, Second , Pregnancy Trimester, Third , Time FactorsABSTRACT
Continuous bromocriptine treatment was given throughout pregnancy to 10 pregnant women with prolactinomas. The dosage of bromocriptine was modified to reduce the serum prolactin level to below 20 ng/ml. Eight patients had continuous bromocriptine treatment started early in their pregnancies, and no tumor-related neurological complications were observed. Continuous bromocriptine treatment was not started at the onset of pregnancy in two patients, and bitemporal hemianopia occurred (at 5 and 7 months of pregnancy). With the start of continuous bromocriptine treatment, a normalization of the visual fields rapidly ensued. The course of the pregnancies and the condition of the newborn infants at birth were normal. The subsequent mental and physical development of the newborn infants (observed up to the age of 6 years) was also normal.
Subject(s)
Bromocriptine/administration & dosage , Hemianopsia/prevention & control , Pituitary Neoplasms/metabolism , Pregnancy Complications, Neoplastic/prevention & control , Prolactin/metabolism , Visual Fields , Adult , Child Development , Child, Preschool , Female , Hemianopsia/drug therapy , Humans , Infant , Infant, Newborn , Male , Pregnancy , Prolactin/blood , Retrospective Studies , Thyrotropin-Releasing HormoneSubject(s)
Bicycling , Nutritional Physiological Phenomena , Sports , Humans , Nutritional RequirementsABSTRACT
The paradoxical association of female pseudohermaphroditism and androgen deficiency was observed in two 46,XX subjects with high corticosterone plasma levels. Subject 1 has been declared a boy due to clitoris enlargement; she had no vagina and uterus. Subject 2 had ambiguous external genitalia. In both, at age 27 and 17 years, fusion of outer labia, impuberism, ovarian cysts, and histologically normal ovarian tissue were observed. Blood pressure was normal. Basal cortisol levels were normal but unresponsive to ACTH. Progesterone levels were 40 and 62 ng/ml and rose after ACTH (50 and 79 ng/ml). 17-hydroxyprogesterone levels were 25 and 21 ng/ml and did not rise after ACTH. Corticosterone levels were 70 and 92 ng/ml and rose after ACTH (110 and 180 ng/ml). All three steroids were suppressed by dexamethasone. Androgen and estrogen levels were at or below the lower limit for normal women. The sex steroid levels obtained by radioimmunoassay in plasma and a follicular cyst fluid were confirmed by isotope dilution-mass spectrometry. We suggest that the sexual ambiguousness resulted from an excessive production of gestagenic steroids during fetal life, and that the enzyme defect is either a partial 17 alpha-hydroxylase defect combined with a peripheral production of 17-hydroxyprogesterone, or else a partial 17-20-desmolase defect with a secondary 21-hydroxylase defect limited to the cortisol pathway.
Subject(s)
Adrenal Hyperplasia, Congenital , Corticosterone/blood , Dexamethasone/therapeutic use , Disorders of Sex Development/etiology , Gonadal Steroid Hormones/biosynthesis , Lyases/deficiency , Ovarian Cysts/etiology , Steroid Hydroxylases/deficiency , Adolescent , Adrenocorticotropic Hormone/pharmacology , Aldosterone/blood , Female , Gonadal Steroid Hormones/blood , Humans , KaryotypingABSTRACT
The level of 25 OH CC in plasma was evaluated in spasmophilia (126 cases) comparatively with normal persons. This level is significantly decreased in spasmophilia. Therapeutic by 25 OH CC of the calcipenic symptoms was tested with good clinical results. Some precautions are necessary when spasmophilia is associated with idiopathic hypercalciura.
Subject(s)
Hydroxycholecalciferols/therapeutic use , Tetany/drug therapy , Calcium/urine , Humans , Hydroxycholecalciferols/administration & dosage , Hydroxycholecalciferols/blood , Tetany/blood , Tetany/urineABSTRACT
One case of chronic hypocalcemia and hyperphosphatemia, with an adult coeliac disease, hight P.T.H. level, very low rate of cyclic A.M.P. in urine, and normal rate of cyclid A.M.P. in plasma is described. It is the question of the pseudohypoparathyroidism acquirec as a result of an adult coeliac disease, because of after seven months of diet without gluten the clinical and biological improvement was observed with the increase of the cyclic-AMP clearance into the normal level and its great reactivity on the administration of exogenous PTH. We think to bring an additional analysis of the trouble of renal receptivity to parathyroid hormone.
Subject(s)
Celiac Disease/complications , Pseudohypoparathyroidism/complications , Adult , Celiac Disease/diet therapy , Female , HumansABSTRACT
The authors consider various aspects of calcium metabolism in pregnant women and the reciprocal influences of endogenous variations in the levels of parathormone, calcitonin, vitamin D, oestrogens and the interferences between calcium metabolism in the mother and that in the foetus. They note the precautions which should be taken for the neonatal calcium balance to be stable.
